A phase II study of obatoclax mesylate (GX15-070MS) in patients with previously-untreated myelodysplastic syndromes (MDS) with anemia and/or thrombocytopenia.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2014
At a glance
- Drugs Obatoclax (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 03 Aug 2012 Company (Teva Pharmaceutical Industries) added as reported by ClinicalTrials.gov.
- 14 Sep 2010 Additional lead trial investigator (Mark Berger) identified as reported by ClinicalTrials.gov.
- 14 Sep 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.